Literature DB >> 20960328

High-field iMRI in glioblastoma surgery: improvement of resection radicality and survival for the patient?

H Maximilian Mehdorn1, Felix Schwartz, Stefan Dawirs, Jürgen Hedderich, Lutz Dörner, Arya Nabavi.   

Abstract

Since the first patients underwent intracranial tumor removal with the radicality control of intraoperative MRI (ioMRI) in September 2005 in our department, the majority of operations performed in the ioMRI room have been indicated for high grade gliomas. In order to elucidate the role of ioMRI scanning in patients harboring high-grade gliomas (HGG) on their survival, one hundred ninety three patients with gliomas WHO grades III and IV were operated either in a standard microsurgical neuronavigated fashion or using additionally ioMRI and were included in a follow-up study. The series started with surgeries from September 2005 until October 2007. Patient attribution to the two groups was based on the logistical availability of the ioMRI on a scheduled surgery day, and on the assumed "difficulty" of the surgery based on the location of the glioma in or near to an eloquent area. Surgery was intended to be as radical as possible without reduction of quality of life. First surgery was performed in 103 patients (75 WHO IV and 28 WHO III) and will be the main topic of this paper. In 60 patients, ioMRI was used, while in 43 patients standard microsurgical neuronavigated resection techniques were applied. Patients were followed in regular intervals mostly until death. Statistical analysis showed a median survival time for patients in whom ioMRI had been used of 20, 37 months compared to 10, 3 months in the cohort who had undergone conventional microsurgical removal. Major influencing concomitants were WHO grades and age which were balanced in both groups.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20960328     DOI: 10.1007/978-3-211-99651-5_16

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  9 in total

Review 1.  Nanotechnology applications for glioblastoma.

Authors:  Edjah K Nduom; Alexandros Bouras; Milota Kaluzova; Costas G Hadjipanayis
Journal:  Neurosurg Clin N Am       Date:  2012-06-14       Impact factor: 2.509

Review 2.  Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy.

Authors:  Mamta Wankhede; Alexandros Bouras; Milota Kaluzova; Costas G Hadjipanayis
Journal:  Expert Rev Clin Pharmacol       Date:  2012-03       Impact factor: 5.045

Review 3.  Current trends in the surgical management and treatment of adult glioblastoma.

Authors:  Richard M Young; Aria Jamshidi; Gregory Davis; Jonathan H Sherman
Journal:  Ann Transl Med       Date:  2015-06

Review 4.  Through the patient's eyes: an emphasis on patient-centered values in operative decision making in the management of malignant glioma.

Authors:  Adam M Robin; Steven N Kalkanis; Jack Rock; Ian Lee; Mark L Rosenblum
Journal:  J Neurooncol       Date:  2014-06-25       Impact factor: 4.130

Review 5.  Surgical resection of malignant gliomas-role in optimizing patient outcome.

Authors:  Ilker Y Eyüpoglu; Michael Buchfelder; Nic E Savaskan
Journal:  Nat Rev Neurol       Date:  2013-01-29       Impact factor: 42.937

6.  Intraoperative image guidance in neurosurgery: development, current indications, and future trends.

Authors:  Chris Schulz; Stephan Waldeck; Uwe Max Mauer
Journal:  Radiol Res Pract       Date:  2012-05-08

7.  A new functional classification system (FGA/B) with prognostic value for glioma patients.

Authors:  Katharina Friedlein; Yavor Bozhkov; Nirjhar Hore; Andreas Merkel; Björn Sommer; Sebastian Brandner; Michael Buchfelder; Nicolai E Savaskan; Ilker Y Eyüpoglu
Journal:  Sci Rep       Date:  2015-07-21       Impact factor: 4.379

8.  Study of freshly excised brain tissues using terahertz imaging.

Authors:  Seung Jae Oh; Sang-Hoon Kim; Young Bin Ji; Kiyoung Jeong; Yeonji Park; Jaemoon Yang; Dong Woo Park; Sam Kyu Noh; Seok-Gu Kang; Yong-Min Huh; Joo-Hiuk Son; Jin-Suck Suh
Journal:  Biomed Opt Express       Date:  2014-07-29       Impact factor: 3.732

9.  Incidentalomas to glioblastoma multiforme.

Authors:  Bobby Sachdev; Jeremy Rees
Journal:  Oxf Med Case Reports       Date:  2014-08-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.